Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | PDE2A | O00408 | 10/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5238900 | 0.81 | BACE1 (0.43) | PDE2ALMNASMN1; SMN2ALDH1A1OPRM1 | |
| SCHEMBL2459503 | 0.80 | CPN1 (0.45) | LMNASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL185475 | 0.79 | PPARG (0.42) | PDE2ALMNASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL2454760 | 0.78 | PDE2A (0.41) | PDE2ALMNASMN1; SMN2HTT | |
| SCHEMBL4943891 | 0.78 | NPC1 (0.42) | PDE2ALMNASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL3974809 | 0.77 | ALDH1A1 (0.48) | LMNASMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL25386581 | 0.76 | ALDH1A1 (0.49) | CNR2LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL15514071 | 0.76 | ALDH1A1 (0.49) | CNR2LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL2589765 | 0.75 | MAPK1 (0.38) | PDE2A | |
| SCHEMBL4170133 | 0.75 | SOAT1 (0.41) | CNR2LMNASMN1; SMN2ALDH1A1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294749-A1 | DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-12-01 | — | — | US | disclosed |
| EP-1518855-B1 | DIAMINOPYRIMIDINECARBOXA MIDE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-8012959-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | ASTELLAS PHARM INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7449456-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA, INC. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20050272753-A1 | Diaminopyrimidinecarboxa mide derivative | ASTELLAS PHARMA INC. (JP) | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294749-A1 | DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE | STAT6, STAT4, STAT3 | CNR2 2470/4885PDE2A 177/4885LMNA 4695/4885 |
| US-20050272753-A1 | Diaminopyrimidinecarboxa mide derivative | STAT5A, STAT6, STAT4 | CNR2 2800/4885PDE2A 271/4885LMNA 3872/4885 |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | STAT6, STAT4, STAT3 | CNR2 2470/4885PDE2A 177/4885LMNA 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.